Streamlining success: How integrated evidence planning transforms asset development
Integrated evidence planning is crucial for aligning evidence generation with stakeholder needs. Explore our robust and actionable insights, with a multistakeholder perspective on optimizing product development and reducing time to market, through strategic evidence generation.
Inside, you'll learn:
- How Integrated Evidence Plans (IEPs) create a path to market approval, access, and uptake
- Practices for IEP implementation and delivery, streamlining and accelerating development
- Strategies to maximize IEP value, including real-world evidence use
- Industry insights on current IEP practices and challenges
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Related Insights
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Blog
Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development
Jun 22, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)
Jan 26, 2022
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023